• Accumetrics (San Diego) said patient enrollment into the GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) trial has begun. The GRAVITAS trial is designed to evaluate the use of the VerifyNow P2Y12 test to identify patients that exhibit a low response to antiplatelet therapy who are at risk for adverse cardiac events, and prove that these at-risk patients will benefit from tailored antiplatelet therapy. The VerifyNow P2Y12 test is a whole blood point-of-care assay that is used to measure the level of P2Y12 receptor blockade. Accumetrics provides diagnostic tests for rapid platelet function assessment.

• Cardiac Science (Bothell, Washington) reported the launch of Pyramis 6.2, the HeartCentrix data management product for the hospital market. The company said Pyramis 6.2 centralizes diagnostic cardiology data for rapid access across all facilities within a hospital network. Pyramis supports hospitals' preferred ECG devices, stress testing equipment, Holter monitors and other devices on a single platform and provides bi-directional communication when paired with most Quinton and Burdick devices. Cardiac Science is a developer of advanced cardiac diagnosis, resuscitation, rehabilitation and informatics products.

• Lantheus Medical Imaging (North Billerica, Massachusetts) presented Phase I data relating to the safety and tolerability in human subjects of BMS747158, its fluorine 18-labeled Positron Emission Tomography (PET) tracer for myocardial perfusion imaging. The preliminary clinical findings indicate that when used with PET technology, BMS747158 demonstrates a favorable radiation dosimetry profile and is generally well-tolerated. The Phase I clinical trial was designed to estimate radiation dosimetry of a single-dose of BMS747158 in healthy subjects at rest. Secondary objectives included assessing human safety, tolerability and biodistribution. Thirteen subjects were injected with 150-260 MBq of BMS747158 intravenously at UCLA Medical Center. Whole body imaging using PET technology was conducted for five hours to collect data for radiation dosimetry calculation. Extensive safety monitoring was conducted with clinical labs, ECG, EEG, neurological, heart rate and blood pressure assessment at several time points during the study. Lantheus specializes in diagnostic imaging.